Meflotas Tablet contains Mefloquine 250 mg, an antimalarial agent indicated for the prevention and treatment of malaria caused by Plasmodium falciparum and other Plasmodium species. Mefloquine acts by interfering with the parasite’s ability to detoxify heme, leading to accumulation of toxic heme metabolites within the parasite, ultimately causing its death. This medication is particularly effective against chloroquine-resistant strains of malaria. Meflotas is prescribed for both prophylaxis in travelers to malaria-endemic regions and for the treatment of acute uncomplicated malaria. The recommended dosage varies depending on the indication and patient weight; for prophylaxis, it is typically administered once weekly starting one to two weeks before exposure and continued for four weeks after leaving the endemic area. For treatment, a higher dose is given as a single or divided dose. Mefloquine should be used with caution in patients with a history of neuropsychiatric disorders, cardiac conduction abnormalities, or hypersensitivity to the drug. Common adverse effects include dizziness, nausea, vivid dreams, and gastrointestinal disturbances. Patients are advised to complete the full course and consult a healthcare professional if adverse reactions occur. Meflotas Tablet is a vital component in malaria management, contributing significantly to global malaria control efforts.